Qiagen NV (QGEN) Receives $39.50 Consensus PT from Brokerages

Qiagen NV (NYSE:QGEN) has received an average rating of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $40.40.

Several analysts have issued reports on QGEN shares. ValuEngine raised Qiagen from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Deutsche Bank increased their target price on Qiagen from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Friday. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Monday, September 17th. Barclays reaffirmed a “buy” rating and set a $43.00 target price on shares of Qiagen in a research report on Thursday, September 6th. Finally, Bank of America increased their target price on Qiagen from $38.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, August 2nd.

NYSE QGEN traded down $0.57 during midday trading on Monday, hitting $35.66. 1,078,200 shares of the company traded hands, compared to its average volume of 959,073. The company has a current ratio of 1.79, a quick ratio of 1.62 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $8.65 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 2.34 and a beta of 1.10. Qiagen has a 52 week low of $30.20 and a 52 week high of $39.45.

Qiagen (NYSE:QGEN) last announced its earnings results on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The business had revenue of $377.20 million for the quarter, compared to analysts’ expectations of $376.89 million. Qiagen had a return on equity of 12.22% and a net margin of 5.26%. On average, equities analysts predict that Qiagen will post 1.33 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Story: Analyst Ratings

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply